Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02399085 · ClinicalTrials.gov registry record · Phase 2
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
A Phase 2 study, sponsored by MorphoSys.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02399085 is a Phase 2 study that has completed, run by MorphoSys. The registered enrollment target is 81 participants.
The verdict
NCT02399085, a Phase 2 study, has completed, sponsored by MorphoSys.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).
Interventions
- DRUG Lenalidomide
- DRUG Tafasitamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-03-29 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02399085
The ClinicalTrials.gov registry entry for NCT02399085 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MorphoSys, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lenalidomide is the first listed.
NCT02399085 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02399085 about?
NCT02399085 is a clinical study titled "Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL". This is a Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL).
What is the current status of trial NCT02399085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2016-03-29. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT02399085?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT02399085?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.